209 related articles for article (PubMed ID: 32127568)
1. Immunogenicity of rat-neu
Sow HS; Benonisson H; Brouwers C; Linssen MM; Camps M; Breukel C; Claassens J; van Hall T; Ossendorp F; Fransen MF; Verbeek JS
Sci Rep; 2020 Mar; 10(1):3933. PubMed ID: 32127568
[TBL] [Abstract][Full Text] [Related]
2. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
3. Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice.
Sharma S; Dominguez AL; Manrique SZ; Cavallo F; Sakaguchi S; Lustgarten J
Cancer Res; 2008 Sep; 68(18):7530-40. PubMed ID: 18794141
[TBL] [Abstract][Full Text] [Related]
4. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
Front Immunol; 2019; 10():1939. PubMed ID: 31475002
[TBL] [Abstract][Full Text] [Related]
5. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
[TBL] [Abstract][Full Text] [Related]
6. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.
Stagg J; Loi S; Divisekera U; Ngiow SF; Duret H; Yagita H; Teng MW; Smyth MJ
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7142-7. PubMed ID: 21482773
[TBL] [Abstract][Full Text] [Related]
7. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.
Gritzapis AD; Voutsas IF; Baxevanis CN
Cancer Immunol Immunother; 2012 Mar; 61(3):397-407. PubMed ID: 21928125
[TBL] [Abstract][Full Text] [Related]
8. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu.
Garrett JT; Rawale S; Allen SD; Phillips G; Forni G; Morris JC; Kaumaya PT
J Immunol; 2007 Jun; 178(11):7120-31. PubMed ID: 17513761
[TBL] [Abstract][Full Text] [Related]
9. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.
D'Amico L; Menzel U; Prummer M; Müller P; Buchi M; Kashyap A; Haessler U; Yermanos A; Gébleux R; Briendl M; Hell T; Wolter FI; Beerli RR; Truxova I; Radek Š; Vlajnic T; Grawunder U; Reddy S; Zippelius A
J Immunother Cancer; 2019 Jan; 7(1):16. PubMed ID: 30665463
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.
Song H; Kim TO; Ma SY; Park JH; Choi JH; Kim JH; Kang MS; Bae SK; Kim KH; Kim TH; Seo SK; Choi IW; Song GA; Mortenson ED; Fu YX; Park S
BMC Cancer; 2014 Sep; 14():647. PubMed ID: 25179116
[TBL] [Abstract][Full Text] [Related]
12. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
[TBL] [Abstract][Full Text] [Related]
13. Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice.
Masuelli L; Marzocchella L; Focaccetti C; Lista F; Nardi A; Scardino A; Mattei M; Turriziani M; Modesti M; Forni G; Schlom J; Modesti A; Bei R
Cancer Immunol Immunother; 2010 Aug; 59(8):1247-58. PubMed ID: 20364378
[TBL] [Abstract][Full Text] [Related]
14. Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors.
Gao Y; Whitaker-Dowling P; Griffin JA; Barmada MA; Bergman I
Cancer Gene Ther; 2009 Jan; 16(1):44-52. PubMed ID: 18654610
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.
Rovero S; Amici A; Di Carlo E; Bei R; Nanni P; Quaglino E; Porcedda P; Boggio K; Smorlesi A; Lollini PL; Landuzzi L; Colombo MP; Giovarelli M; Musiani P; Forni G
J Immunol; 2000 Nov; 165(9):5133-42. PubMed ID: 11046045
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.
Croci S; Nanni P; Palladini A; Nicoletti G; Grosso V; Benegiamo G; Landuzzi L; Lamolinara A; Ianzano ML; Ranieri D; Dall'Ora M; Iezzi M; De Giovanni C; Lollini PL
Breast Cancer Res; 2015 May; 17(1):70. PubMed ID: 25997501
[TBL] [Abstract][Full Text] [Related]
17. Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells.
Mortenson ED; Park S; Jiang Z; Wang S; Fu YX
Clin Cancer Res; 2013 Mar; 19(6):1476-86. PubMed ID: 23363817
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice.
Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Cipriani B; Forni G; Monaci P
Int J Cancer; 2007 Feb; 120(3):574-84. PubMed ID: 17096348
[TBL] [Abstract][Full Text] [Related]
19. Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice.
Orlandi F; Guevara-Patiño JA; Merghoub T; Wolchok JD; Houghton AN; Gregor PD
Vaccine; 2011 May; 29(20):3646-54. PubMed ID: 21435405
[TBL] [Abstract][Full Text] [Related]
20. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
Masuelli L; Focaccetti C; Cereda V; Lista F; Vitolo D; Trono P; Gallo P; Amici A; Monaci P; Mattei M; Modesti M; Forni G; Kraus MH; Muraro R; Modesti A; Bei R
Int J Oncol; 2007 Feb; 30(2):381-92. PubMed ID: 17203220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
